NCT01843374进行中（未招募）2 期
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 571
- 试验地点
- 105
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period.
详细描述
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo.
Randomization will be stratified by EORTC status (low-risk vs high-risk), line of therapy (second vs third), and anatomical site (pleural vs peritoneal). This study plans to use the EORTC to stratify subjects into high or low risk groups in order to ensure balanced randomization to the different treatment groups. For subjects in whom pemetrexed was contraindicated or not tolerated or not an approved therapy (eg, peritoneal mesothelioma), prior therapy with a first-line platinum-based regimen is required. Approximately 564 subjects will be enrolled at study centers in multiple countries.
The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically and/or cytologically confirmed pleural or peritoneal malignant mesothelioma;
- •Disease not amenable to curative surgery;
- •Age 18 and over at the time of consent;
- •ECOG Performance status 0-1;
- •Progressed after previous receipt of 1-2 prior systemic treatments for advanced disease that included a first-line pemetrexed (or anti-folate)-based regimen in combination with platinum agent.
- •Recovered from all toxicities associated with prior treatment, to acceptable baseline status, or a NCI CTCAE Grade of 0 or 1, except for toxicities not considered a safety risk,
- •Measurable diseaseby modified RECIST for pleural mesothelioma or RECIST v1.1 for peritoneal mesothelioma;
- •Adequate bone marrow, hepatic, and renal function determined within 14 days prior to randomization defined as:
- •Negative screening test results for human immunodeficiency virus (HIV), hepatitis A, B and C.
- •Written informed consent and any locally required authorization (eg, HIPAA in the USA, EU Data Privacy Directive authorization in the EU) obtained from the subject/legal representative prior to performing any protocol- related procedures, including screening evaluations;
- •Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 6 months after the final dose of investigational product; cessation of contraception after this point should be discussed with a responsible physician.
- •Nonsterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from Days 1 through 90 post last dose. In addition, they must refrain from sperm donation for 90 days after the final dose of investigational product.
排除标准
- •Subjects who failed more than 2 prior systemic treatment regimens for advanced malignant mesothelioma;
- •Received any prior mAb against CTLA-4, programmed cell death 1 (PD1) or programmed cell death 1 ligand 1 (PD-L1);
- •History of chronic inflammatory or autoimmune disease with symptomatic disease within the last 3 years prior to randomization.
- •Active, untreated central nervous system (CNS) metastasis
- •Any serious uncontrolled medical disorder or active infection that would impair the subject's ability to receive investigational product;
- •History of other malignancy unless the subject has been disease-free for at least 3 years;
- •Pregnant or breast feeding at time of consent;
- •Any condition that would prohibit the understanding or rendering of information and consent and compliance with the requirements of this protocol;
- •Active or history of diverticulitis;
- •Active or history of inflammatory bowel disease, irritable bowel disease, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea. Active or history of systemic lupus erythematosus or granulomatosis with polyangiitis;
- •History of sarcoidosis syndrome;
- •Currently receiving systemic corticosteroids or other immunosuppressive medications or has a medical condition that requires the chronic use of corticosteroids.
- •Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment;
- •The last dose of prior chemotherapy or radiation therapy was received less than 2 weeks prior to randomization;
- •Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of vitiligo and alopecia;
- •Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results;
- •Concurrent enrollment in another clinical study or receipt of an investigational product within the last 4 weeks
- •Employees of the study site directly involved with the conduct of the study, or immediate family members of any such individuals;
- •Subjects with a history of hypersensitivity to compounds of similar biologic composition to tremelimumab or any constituent of the product.
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
Tremelimumab
Experimental
Tremelimumab
干预措施: Tremelimumab (Drug)
结局指标
主要结局
Overall Survival (OS)
时间窗: 3 years.
Overall survival (OS) by treatment arm
次要结局
- OS Rate at 18 Months by Treatment Arm(18 months)
- Progression-free Survival by Treatment Arm(Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years.)
- Overall Response Rate by Treatment Arm(Time from randomization to best response to treatment, assessed up to 3 years.)
- Duration of Response by Treatment Arm(Duration of response from the first documentation of objcetive response (confirmed CR or PR) to the first documented disease progression, assessed up to 14 weeks after the initial response.)
- Disease Control Rate by Treatment Arm(Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years.)
- Durable Disease Control Rate by Treatment Arm(Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years.)
- Number of Participants Reporting Any Adverse Event(Day 1- 90 days post dose)
- Number of Participants Reporting Any Serious Adverse Events(Day 1 to 90 days post dose)
- Number of Participants With Positive Anti-drug Antibodies(Week 5)
研究者
研究点 (105)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety on SOM3355 in Huntington's Disease ChoreaHuntington ChoreaNCT05475483SOM Innovation Biotech SA139
进行中（未招募）
1 期
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant MesotheliomaEUCTR2012-003524-21-GBMedImmune, LLC564
进行中（未招募）
1 期
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant MesotheliomaCTIS2024-511841-20-00AstraZeneca AB223
已完成
2 期
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesotheliomainoperabel maligne mesothelioomPleural or Peritoneal MesotheliomaNL-OMON41613Medimmune LLC, subsidiary of AstraZeneca32
进行中（未招募）
不适用
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant MesotheliomaEUCTR2012-003524-21-NLMedImmune, LLC564